Login / Signup

Efficacy and Safety of Secukinumab in the Treatment of Psoriasis in Patients with Skin Phototypes IV to VI.

Nour El-KashlanAhuva CicesBridget KaufmanJoel Correa Da RosaIngrid Sanabria-GonzalezSaakshi KhattriAndrew Alexis
Published in: Journal of drugs in dermatology : JDD (2024)
Secukinumab 300 mg administered monthly was safe, well-tolerated, and efficacious in treating skin of color patients with psoriasis and improving health-related quality of life. Larger studies involving skin of color populations with psoriasis are warranted. J Drugs Dermatol. 2024;23(8):600-606. doi:10.36849/JDD.8128.
Keyphrases
  • soft tissue
  • wound healing
  • ankylosing spondylitis
  • atopic dermatitis
  • rheumatoid arthritis
  • smoking cessation